Literature DB >> 17241713

The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors.

Joeli A Brinkman1, Xuemei Xu, W Martin Kast.   

Abstract

A majority of cervical cancers are associated with Human Papillomavirus (HPV)-16. A DNA vaccine (E7IR) was designed for prophylactic and therapeutic treatment of HPV-16+ tumors containing two repeats of the E7 gene to inactivate transformation and duplicate available epitopes. Mice were vaccinated then tumor challenged, or challenged and then immunized and monitored for tumor volume and survival. Splenocytes were utilized for in vivo CTL assays. The E7IR vaccine demonstrated decreased tumor volume and enhanced survival in prophylactic and therapeutic experiments and improved CTL-mediated lysis. The E7IR vaccine shows promise in prevention of tumor formation and elimination of established tumors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17241713      PMCID： PMC1885421          DOI： 10.1016/j.vaccine.2006.12.045

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  31 in total

Review 1.  Modifying professional antigen-presenting cells to enhance DNA vaccine potency.

Authors:  Chien-Fu Hung; Mu Yang; T C Wu
Journal:  Methods Mol Med       Date:  2006

Review 2.  Vaccine developments.

Authors:  M A Liu
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine.

Authors:  M P Velders; S Weijzen; G L Eiben; A G Elmishad; P M Kloetzel; T Higgins; R B Ciccarelli; M Evans; S Man; L Smith; W M Kast
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

4.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.

Authors:  W Osen; T Peiler; P Ohlschläger; S Caldeira; S Faath; N Michel; M Müller; M Tommasino; I Jochmus; L Gissmann
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

Review 6.  The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.

Authors:  J A Brinkman; A S Caffrey; L I Muderspach; L D Roman; W M Kast
Journal:  Eur J Gynaecol Oncol       Date:  2005       Impact factor: 0.196

7.  Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

Authors:  Shiwen Peng; Hongxiu Ji; Cornelia Trimble; Liangmei He; Ya-Chea Tsai; Jessica Yeatermeyer; David A K Boyd; Chien-Fu Hung; T-C Wu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.

Authors:  W C Phelps; C L Yee; K Münger; P M Howley
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

9.  An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.

Authors:  Peter Ohlschläger; Michaela Pes; Wolfram Osen; Matthias Dürst; Achim Schneider; Lutz Gissmann; Andreas M Kaufmann
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

10.  Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization.

Authors:  M Dürst; D Glitz; A Schneider; H zur Hausen
Journal:  Virology       Date:  1992-07       Impact factor: 3.616
View more
  8 in total

1.  DNA vaccines for cervical cancer.

Authors:  Chien-Fu Huang; Archana Monie; Wei-Hung Weng; Tc Wu
Journal:  Am J Transl Res       Date:  2010-01-02       Impact factor: 4.060

Review 2.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

3.  Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.

Authors:  John B Liao; Jean Publicover; John K Rose; Daniel DiMaio
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

4.  The future of vaccines for cervical cancer.

Authors:  Warner K Huh; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2008-05       Impact factor: 5.482

5.  Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region.

Authors:  Yi Zheng; Yijuan Zhang; Yuandong Ma; Jun Wan; Chaofan Shi; Laiqiang Huang
Journal:  J Microbiol       Date:  2008-12-24       Impact factor: 3.422

Review 6.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

Review 7.  Therapeutic HPV DNA vaccines.

Authors:  Archana Monie; Shaw-Wei D Tsen; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

8.  Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors.

Authors:  Juan Martin Caballero; Ana Garzón; Leticia González-Cintado; Wioleta Kowalczyk; Ignacio Jimenez Torres; Gloria Calderita; Margarita Rodriguez; Virgínia Gondar; Juan Jose Bernal; Carlos Ardavín; David Andreu; Thomas Zürcher; Cayetano von Kobbe
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.